$0.00
Shopping Cart
Facebook-f Instagram
Donate

Clinical Trial Record

Return to Clinical Trials

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients

2022-03-25

2025-06-30

2025-12-31

0

Study Overview

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients

An exploratory clinical study to evaluate the safety and efficacy of NK cells (combined with standard therapy) in the treatment of solid tumor patients

N/A

  • Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)
  • DRUG: Allogeneic NK（CCT-ANK-11)
  • CCT-ANK-11

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2024-02-21  

N/A  

2024-04-14  

2024-02-21  

N/A  

2024-04-16  

2024-02-28  

N/A  

2024-02  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: A group

DRUG: Allogeneic NK（CCT-ANK-11)

  • allogeneic natural killer cells
Primary Outcome MeasuresMeasure DescriptionTime Frame
To evaluate the safety and the efficacyTo evaluate the safety and objective remission rate of multiple injections of allogeneic natural killer cells (complete remission [CR] + partial remission [PR])12 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. The patient agrees to complete the entire treatment plan and sign the informed consent form. 2. Age 18 to 65, male or female. 3. Malignancy confirmed by histology or imaging diagnosis (computer tomography (CT), magnetic resonance imaging (MRI), contrast-enhanced ultrasound, EOB-MRI), the malignant solid tumor was completely resected (R0). 4. Patients who have received surgical treatment 4-8 weeks before the screening period. 5. Quality of life assessment form (ECOG) score 0,2. 6. Child-Pugh score of liver function ≤ 7. 7. The life expectancey is more than 6 months. 8. Patients with appropriate hematological functions:
    （1）White blood cell (WBC) ≥ 3000 cells / mm3. （2）Absolute neutrophil count (ANC) ≥ 1500 cells.
    （3）Platelet count (Platelets) ≥ 80000/mm3. （4）Hemoglobin (Hb) ≥ 9g/dl. 9. Patients with appropriate liver and kidney functions:
    （1）Urea nitrogen (BUN) ≤ 1.5 times of the upper limit of normal value (ULN).（2）Serum creatinine (serumcreatinine) ≤ 1.5 times of the upper limit of normal value (ULN).（3）Total bilirubin (TB) ≤ 1.5 times of the upper limit of normal value (ULN).（4）Glutamic pyruvic transaminase (ALT or GPT) and glutamic oxaloacetic transaminase (AST or GOT) ≤ 2.5 times the upper limit of normal value (ULN).
    10. Patients who have tested negative for syphilis and AIDS. 11.Patient with active hepatitis B, can take antiviral drugs during the trial period.
    twelve。 Fertile men and women must use effective contraception within 14 days after signing the informed consent form and within 14 days after the last dose of natural killer cells are infused.
    13. At least two forms of birth control must be used, one of which must be a barrier method. Acceptable contraceptive measures include:
    （1）Establish oral, injection or implanted hormone contraceptive methods.（2）Placement of intrauterine device (IUD) or intrauterine system (IUS).（4）Barrier method: condom or occlusive cap (contraceptive diaphragm or cervical / uterine cap).
    14. The patient agrees to comply to the trial rpotocols.
    Exclusion Criteria:
    1. Patients received drugs or other cellular immunotherapy in other clinical trials within 28 days before the screening period. 2. Patients are receiving immunosuppressive therapy for previous or recurrent autoimmune diseases within 14 days before allogeneic natural killer cell infusion. 3. The patient suffered from other malignant tumors in the past 5 years (except basal cell carcinoma or squamous cell carcinoma of the skin and carcinoma in situ of the cervix). 4. Acute illness in progress, or has been accompanied by serious diseases in the past 2 years, such as cardiovascular disease (such as New York Heart Association (NYHA) III or IV), mental health problems (e.g. alcohol, drug abuse). Or the program moderator judges patients who are not suitable to participate in clinical trials on the basis of medical history, physical examination results or test abnormalities that may interfere with the test results or adversely affect the safety of the subjects. 5. Allergic to aminoglycosides (Aminoglycoside) or subtilisin (Bacitracin), such as streptomycin (Streptomycin) and gentamicin (Gentamicin). 6. Patient is known to be allergic to any ingredient in the end product of NK preparation, including human serum albumin. 7. Female subjects who are breast-feeding or positive for serum or urine pregnancy tests during the screening period. 8. Pretreatment with steroids or antihistamines cannot be controlled for radiographic contrast agents (iodinated or non-iodinated) who have a history of allergy or allergic reactions or other clinically significant adverse reactions, and the researchers believe that it is not suitable for subjects who undergo conventional computerized tomography (CT) or magnetic resonance imaging (MRI). And subjects with contraindications for CT scanning for other reasons (such as strong magnetic implants, severe claustrophobia) should not be included in the group.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Treat yourself

Let Us Take Care Of You

BOOK AN APPOINTMENT ⟶

About

Events

Fundraising

Contact Us

Facebook-f Instagram

NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved

Make-A-Will Month

Learn More
Donate Now Online
Other Ways to Donate